Bosentan

證據等級: L5

預測適應症: 9 個

Bosentan: From Pulmonary Arterial Hypertension to Rheumatoid Arthritis

One-Sentence Summary

Bosentan is a dual endothelin receptor (ETA/ETB) antagonist historically used for pulmonary arterial hypertension (PAH), though formal original-indication data was not captured in this evidence pack (data gap). The TxGNN model predicts it may be effective for Rheumatoid Arthritis, with 1 clinical trial and 15 publications currently associated with this direction — but the evidence is largely mechanistic/preclinical, and the single registered trial actually targets a different disease (Giant Cell Arteritis).

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (0 Taiwan licenses on file). Bosentan is generally known as an endothelin receptor antagonist developed for pulmonary arterial hypertension — not confirmed by the data provided here (see DG001/DG002).
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	99.80%
Evidence Level	L4 (preclinical / mechanistic studies only)
Taiwan Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (data gap DG002). Based on known pharmacology, Bosentan is a dual endothelin receptor antagonist (ETA/ETB), and its efficacy in pulmonary arterial hypertension is well established through blockade of endothelin-1 (ET-1)-mediated vasoconstriction.

The mechanistic rationale for rheumatoid arthritis (RA) rests on the observation that ET-1 levels are elevated in RA synovial tissue, and animal models (collagen-induced arthritis, zymosan-induced arthritis) show that ETA/ETB blockade reduces TNF-α, LTB4, and other inflammatory mediators. IL-15 and IL-17-driven nociception in arthritis models has also been shown to be attenuated by dual ET receptor antagonism. These findings suggest a biologically plausible anti-inflammatory role for endothelin blockade in joint disease.

However, this link remains indirect and unproven in humans. The only registered clinical trial associated with this prediction (NCT06957002) is a Phase 2 study of Bosentan in Giant Cell Arteritis, not rheumatoid arthritis — a related but distinct rheumatic condition. No RA-specific human trial currently exists, so this prediction should be treated as a research hypothesis rather than a clinically validated indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06957002	Phase 2	Not Yet Recruiting	40	Multicenter RCT testing Bosentan + glucocorticoids vs. glucocorticoids alone for failure-free survival at 12 months — note: enrolled population is Giant Cell Arteritis (GCA), not RA; relevance graded "C" (mechanistic proxy only)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22249931	2012	Preclinical (animal)	Inflammation Research	Bosentan ameliorates collagen-induced arthritis in mice; TNF-α drives induction of endothelin system genes
18515326	2008	Preclinical (animal)	Journal of Leukocyte Biology	ET receptor blockade modulates neutrophil accumulation and edema in zymosan-induced arthritis; ET-1 elevated in RA synovium
19969421	2010	Preclinical (animal)	Pain	IL-17-mediated articular hypernociception in antigen-induced arthritis; ET pathway implicated in RA pain signaling
16766656	2006	Preclinical (animal)	PNAS	IL-15-driven inflammatory hypernociception (relevant to RA) inhibited by dual ETA/ETB receptor antagonism
24268012	2014	Review	Rheumatic Diseases Clinics of North America	Reviews PAH associated with connective tissue disease, including RA, and current ERA-based treatment options
16218473	2005	Review	Lupus	Reviews PAH complicating connective tissue diseases including RA; discusses ET-1 pathophysiology
20054770	2009	Case report	Kardiologia Polska	Pediatric case of Eisenmenger syndrome + juvenile RA treated with Bosentan; clinical improvement noted
19487226	2009	Review	Rheumatology (Oxford)	Reviews vasculopathy and PAH in autoimmune/rheumatic disease context

Taiwan Market Information

Bosentan currently has 0 authorizations on file and is not marketed in Taiwan per this evidence pack.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data were not available in this evidence pack — flagged as Blocking data gap DG001, required before any S1 safety pre-assessment can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction (Rheumatoid Arthritis) is supported only by preclinical/mechanistic evidence (L4) and animal models of arthritis; the sole registered trial targets a different disease (Giant Cell Arteritis, not RA). No completed human RA trial or RCT data exists to justify advancing this indication at this time.

To proceed, the following is needed:

A dedicated RA-specific clinical trial or at minimum a Phase 2 proof-of-concept study
TFDA/regulatory-grade package insert data (warnings, contraindications, DDI) — currently a Blocking gap (DG001)
Confirmed mechanism of action documentation (DG002)
Formal Taiwan regulatory pathway, given the drug is currently unmarketed (0 licenses)

Note for reviewers: Within the same evidence pack, limited systemic sclerosis (rank 3, TxGNN score 99.65%) shows substantially stronger evidence — a systematic review/meta-analysis, a 300-patient observational study, and multiple mechanistic papers on Bosentan reversing endothelial-to-mesenchymal transition — reaching evidence level L2 with a "Proceed with Guardrails" recommendation. This candidate may warrant prioritization over the RA hypothesis for near-term development.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.